醫療科技評估 Health Technology Assessment
連結醫藥科技研究與政策決定的橋樑 is the systematic evaluation of properties, effects, and/or impacts of health technology

產業輔導

3. 我國政府成立醫藥科技評估專責單位的緣起? How was the dedicated HTA agency established in Taiwan?

發佈日期:
點閱次數:455

       在民國96年初的衛生署高階主管共識營會議中,侯勝茂署長指示,醫療科技評估制度非常重要,必須有效加以推動,決定設在財團法人醫藥品查驗中心(CDE)。民國97年4月1日醫藥科技評估組正式成立,接受衛生署四年期中綱計畫補助,其任務為建立我國透明且符合科學性之醫療科技評估制度,並以「實證基礎為導向」執行主管機關所委託之醫療科技評估業務。主要是協助行政院衛生福利部中央健康保險署對廠商提出之新藥、新特材給付建議案件進行療效與經濟評估(包括臨床相對療效、成本效益與預算衝擊等)、相關科學實證的蒐集、與我國適用性等分析報告,以作為全民健康保險新藥新特材收載審議之參考。

 

In a Department of Health executives' consensus meeting held in early 2007, the Minister Sheng-Mou Hou decided to set up a HTA Division within the Center for Drug Evaluation (CDE) to assist the decision making of Bureau of National Health Insurance (now National Health Insurance Administration) when a new drug was introduced into the market. The HTA Division was officially established on Apr 1, 2008, funded by government grant. Its mission was to establish a transparent, evidence-based health technology assessment system in Taiwan. Its function was to perform efficacy and economic analysis (including comparative clinical efficacy, cost-effectiveness and budget impact analysis), gathering relevant scientific evidence and performing local applicability analysis on pharmaceutical reimbursement applications submitted to the National Health Insurance Administration (NHIA) of the Ministry of Health and Welfare (MOHW), Executive Yuan. The HTA analysis results were used to assist the decision making process for reimbursement listing.